What is ICD-10 code D70.2?

D70.2 is the ICD-10-CM diagnosis code for Other drug-induced agranulocytosis. A low white blood cell count caused by medications other than chemotherapy drugs. It belongs to the ICD-10-CM chapter for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (d50-d89). D70.2 is a billable code, meaning it can be reported on a claim as a primary or secondary diagnosis when supported by documentation. D70.2 is part of the FY2026 ICD-10-CM code set published by the CMS National Center for Health Statistics and used on Medicare, Medicaid, and commercial claims in the United States.

Yes. D70.2 is a billable ICD-10-CM code that can be reported on professional and institutional claims as a primary or secondary diagnosis when the provider documentation supports the specific condition described. Billable codes in ICD-10-CM are coded to the highest level of specificity available for the documented diagnosis. D70.2 is current for fiscal year 2026 and remains in the active CMS ICD-10-CM code set published by the National Center for Health Statistics.

What is the V28 vs V24 difference for D70.2?

CMS phased in the V28 risk adjustment model over payment years 2024 (33%), 2025 (67%), and 2026 (100%), replacing V24. V28 consolidates HCC categories, removes some lower-acuity conditions, and recalibrates RAF weights across the entire model. D70.2 was a payment HCC under V24 (Disorders of Immunity) but the V28 recalibration removed it from the risk adjustment model. Both models can still appear in legacy data and in payer-specific lookback periods.

What should coders know when reporting D70.2?

Document the specific medication causing the agranulocytosis in the medical record for clarity Differentiate from D70.1 (chemotherapy-induced) by confirming the offending drug is not a cancer treatment Because D70.2 maps to a payment HCC, the documentation must also satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's risk adjustment score.

D70.2: Other drug-induced agranulocytosis — ICD-10

ICD-10-CM Code View

HCC Buddy Code Card

Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.

Code lookupD70.2Effective periodFY2026 Apr Update (Apr 1-Sep 30)

FY 2026 Apr update / Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89) / Other disorders of blood and blood-forming organs (D70-D77)

D70.2

Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidance

Other drug-induced agranulocytosis

A low white blood cell count caused by medications other than chemotherapy drugs.

Buddy Insight

CMS-HCC V28

Not risk-adjusted for this model/period.

RAF 0

CMS-HCC V24

Mapped

HCC 47

Disorders of Immunity

RAF 0.472

ACA/HHS

Not risk-adjusted for this model/period.

RAF 0

ESRD/PACE

Mapped

HCC 47

Disorders of Immunity

RAF 0.0

RXHCC

Not risk-adjusted for this model/period.

RAF 0

Code Trumping

Basket needed

Compare selected patient codes to show trumped or trumps impact.

Code Book Path

Official

D70Neutropenia

D70.2Other drug-induced agranulocytosis

Inclusion Terms

Official

ICD-10-CM does not list inclusion terms for D70.2 in this effective period.

Excludes 2

Official

ICD-10-CM does not list Excludes 2 notes for D70.2 in this effective period.

Related Child Codes

Official

D70.0Congenital agranulocytosis

D70.1Agranulocytosis secondary to cancer chemotherapy

D70.3Neutropenia due to infection

D70.4Cyclic neutropenia

D70.8Other neutropenia

Includes

Official

agranulocytosis
decreased absolute neurophile count (ANC)

Excludes 1

Official

neutropenic splenomegaly (D73.81)
transient neonatal neutropenia (P61.5)

Code First

Official

ICD-10-CM does not list Code First sequencing instructions for D70.2 in this effective period.

Use Additional

Official

code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)

Code Also

Official

, if applicable, mucositis (J34.81, K12.3-, K92.81, N76.81)

Buddy Documentation Tip

HCC Buddy guidance

Document the offending medication, temporal relationship between drug initiation and neutropenia onset, absolute neutrophil count nadir, and response after drug discontinuation.

Record the adverse effect T-code for the specific medication, any infectious complications, and G-CSF use.

Note whether the medication was restarted or a substitute was used.

MEAT Support

HCC Buddy guidance

Document the offending medication, temporal relationship between drug initiation and neutropenia onset, absolute neutrophil count nadir, and response after drug discontinuation.

Record the adverse effect T-code for the specific medication, any infectious complications, and G-CSF use.

Note whether the medication was restarted or a substitute was used.

Audit Caution

HCC Buddy guidance

Always pair D70.2 with the appropriate adverse effect T-code identifying the causative medication.

Clozapine-associated agranulocytosis requires specific monitoring protocols — document compliance with mandated blood count monitoring.

Distinguish from dose-dependent medication effects (chemotherapy) which use D70.1.

Common Mistakes

HCC Buddy guidance

D70.1 (Agranulocytosis secondary to cancer chemotherapy) — expected dose-dependent effect versus idiosyncratic drug reaction

D70.8 (Other neutropenia) — non-drug-related acquired neutropenia

D70.9 (Neutropenia, unspecified) — should specify drug-induced cause when documented.

Last updated: FY2026 ICD-10-CM Apr update, Apr 1, 2026 through Sep 30, 2026. CMS-HCC V28 is 100% phased in for payment year 2026.

Is D70.2 an HCC code?

Yes. D70.2 maps to Disorders of Immunity under the V24 model but is not retained in V28.

HCC Category Mapping

V24HCC 47, Disorders of Immunity

0.472

ESRDHCC 47, Disorders of Immunity

0.000

RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.

MEAT Criteria for D70.2

For D70.2to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically, it has to be re-documented and supported each calendar year.

MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
EEvaluate: test results, medication response, or physical findings reviewed by the provider
AAssess: explicit mention in the assessment or plan with acknowledgment of status
TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis

Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed D70.2 during that encounter, not just copy-forwarded from a problem list.

What This Code Means

D70.2 is the ICD-10-CM diagnosis code for other drug-induced agranulocytosis. A low white blood cell count caused by medications other than chemotherapy drugs. D70.2 sits in the ICD-10-CM chapter for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (d50-d89), within the section covering other disorders of blood and blood-forming organs (d70-d77).

Under the older CMS-HCC V24 model, D70.2 maps to Disorders of Immunity (HCC 47) with a community, non-dual, aged base RAF weight of 0.472. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.

Document the specific medication causing the agranulocytosis in the medical record for clarity. Because D70.2 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.

HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for D70.2 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.

Coding Tips

•Document the specific medication causing the agranulocytosis in the medical record for clarity
•Differentiate from D70.1 (chemotherapy-induced) by confirming the offending drug is not a cancer treatment

Clinical Significance

Other drug-induced agranulocytosis captures severe neutropenia caused by non-chemotherapy medications, including antithyroid drugs (methimazole, propylthiouracil), clozapine, sulfasalazine, dapsone, and certain antibiotics. This is an idiosyncratic reaction that can be life-threatening and requires immediate drug discontinuation. Unlike chemotherapy-induced neutropenia, it is unpredictable and not dose-dependent.

Documentation Requirements

✓Document the offending medication, temporal relationship between drug initiation and neutropenia onset, absolute neutrophil count nadir, and response after drug discontinuation.
✓Record the adverse effect T-code for the specific medication, any infectious complications, and G-CSF use.
✓Note whether the medication was restarted or a substitute was used.

Use Additional Code

code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)

Commonly Confused Codes

•D70.1 (Agranulocytosis secondary to cancer chemotherapy): expected dose-dependent effect versus idiosyncratic drug reaction
•D70.8 (Other neutropenia): non-drug-related acquired neutropenia
•D70.9 (Neutropenia, unspecified): should specify drug-induced cause when documented.